The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
3 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $1,065,582 in first-year total cost, median $339,620.
Most frequent study sections
- Special Emphasis Panel[ZNS1 SRB-T (34)]1
- Special Emphasis Panel[ZNS1 SRB-T (41)]1
- Special Emphasis Panel[ZNS1 SRB-T (44)]1
Most frequent institutions
- ANAGIN1
- ENCEPHEAL THERAPEUTICS, INC.1
- SITEONE THERAPEUTICS, INC.1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2021 | Discovery of PSD95 protein-protein interaction inhibitors as novel non-opioid analgesics1U44NS119284-01 | FLORIO, STEPHANIE K | ANAGIN, IN | $499,786 | ZNS1 |
| 2020 | Novel Atypical Dopamine Modulators as Cocaine Pharmacotherapies1U44NS116931-01 | CHILDERS, STEVEN R | ENCEPHEAL THERAPEUTICS, INC., NC | $339,620 | ZNS1 |
| 2019 | Discovery of NaV1.7 Inhibitors for the Treatment of Pain1U44NS111779-01 | MULCAHY, JOHN VINCENTODINK, DEBRA | SITEONE THERAPEUTICS, INC., CA | $226,176 | ZNS1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.